RhumbLine Advisers’s Trillium Therapeutics Inc. TRIL Stock Holding History

RhumbLine Advisers’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-132,421	Closed	-$2.33M	–	3051
2021 Q3	$2.33M	Buy	132,421 +4,038	+3%	+$47.2K	﹤0.01%	1821
2021 Q2	$1.25M	Buy	+128,383	New	+$1.21M	﹤0.01%	2146

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

RhumbLine Advisers's TRIL Position: Q4 2021 in Review

RhumbLine Advisers sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 132,421 shares — an estimated $2.33M sold.

RhumbLine Advisers first reported a position in TRIL in Q2 2021 and held it in 2 quarters. The position peaked at $2.33M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

RhumbLine Advisers reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
RhumbLine Advisers sold 132,421 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $2.33M.
RhumbLine Advisers first reported a position in Trillium Therapeutics Inc. in Q2 2021 and held it in 2 quarters.
RhumbLine Advisers's Trillium Therapeutics Inc. position peaked at $2.33M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on RhumbLine Advisers's 13F filing for Q4 2021, filed 10 Feb 2022.